Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyTiratricol
Identification
- Name
- Tiratricol
- Accession Number
- DB03604 (EXPT00217, DB12922)
- Type
- Small Molecule
- Groups
- Investigational
- Description
A metabolite of T3 and T4 thyroid hormones; promoted for hyperlipidemia, localized lipodystrophy, and obesity. Tiratricol has been used in trials studying the treatment of Allan-Herndon-Dudley Syndrome.
- Structure
Structure for Tiratricol (DB03604)
- Synonyms
- 3',3,5-Triiodothyroacetic acid
- Tiratricolum
- Triacana
- Triiodothyroacetic acid
- Product Ingredients
Ingredient UNII CAS InChI Key Tiratricol sodium 3HK9045D54 1477-04-9 BBBAIWCYEJXUMH-UHFFFAOYSA-M - Categories
- UNII
- 29OQ9EU4R1
- CAS number
- 51-24-1
- Weight
- Average: 621.9323
Monoisotopic: 621.763489036 - Chemical Formula
- C14H9I3O4
- InChI Key
- UOWZUVNAGUAEQC-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H9I3O4/c15-9-6-8(1-2-12(9)18)21-14-10(16)3-7(4-11(14)17)5-13(19)20/h1-4,6,18H,5H2,(H,19,20)
- IUPAC Name
- 2-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid
- SMILES
- OC(=O)CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UThyroid hormone receptor beta Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction (R)-warfarin Tiratricol may increase the anticoagulant activities of (R)-warfarin. (S)-Warfarin Tiratricol may increase the anticoagulant activities of (S)-Warfarin. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Tiratricol. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Tiratricol. 3-isobutyl-1-methyl-7H-xanthine The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Tiratricol. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Tiratricol. 4-hydroxycoumarin Tiratricol may increase the anticoagulant activities of 4-hydroxycoumarin. 6-O-benzylguanine The serum concentration of 6-O-benzylguanine can be increased when it is combined with Tiratricol. 7-Deazaguanine The serum concentration of 7-Deazaguanine can be increased when it is combined with Tiratricol. 7,9-Dimethylguanine The serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Tiratricol. - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5803
- PubChem Substance
- 46504696
- ChemSpider
- 5598
- BindingDB
- 18862
- ChEMBL
- CHEMBL41632
- IUPHAR
- 2637
- Guide to Pharmacology
- GtP Drug Page
- HET
- 4HY
- Wikipedia
- Tiratricol
- ATC Codes
- H03AA04 — Tiratricol
- H03AA — Thyroid hormones
- H03A — THYROID PREPARATIONS
- H03 — THYROID THERAPY
- H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
- PDB Entries
- 1nq0 / 1nq1 / 1nq2 / 1nuo / 2pin / 2pit / 2piu / 2pkl / 2qpy / 3d57 … show 3 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Not Yet Recruiting Treatment Allan-Herndon-Dudley Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00539 mg/mL ALOGPS logP 5.27 ALOGPS logP 5.59 ChemAxon logS -5.1 ALOGPS pKa (Strongest Acidic) 2.31 ChemAxon pKa (Strongest Basic) -6.4 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 66.76 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 105.67 m3·mol-1 ChemAxon Polarizability 40.54 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.6831 Blood Brain Barrier + 0.7944 Caco-2 permeable + 0.628 P-glycoprotein substrate Non-substrate 0.5904 P-glycoprotein inhibitor I Non-inhibitor 0.8432 P-glycoprotein inhibitor II Non-inhibitor 0.9274 Renal organic cation transporter Non-inhibitor 0.8986 CYP450 2C9 substrate Non-substrate 0.7944 CYP450 2D6 substrate Non-substrate 0.9201 CYP450 3A4 substrate Non-substrate 0.6595 CYP450 1A2 substrate Inhibitor 0.7505 CYP450 2C9 inhibitor Inhibitor 0.8948 CYP450 2D6 inhibitor Non-inhibitor 0.9333 CYP450 2C19 inhibitor Non-inhibitor 0.9026 CYP450 3A4 inhibitor Non-inhibitor 0.8679 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6166 Ames test Non AMES toxic 0.9047 Carcinogenicity Non-carcinogens 0.8759 Biodegradation Not ready biodegradable 0.975 Rat acute toxicity 3.8459 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.939 hERG inhibition (predictor II) Non-inhibitor 0.8942
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylethers
- Direct Parent
- Diphenylethers
- Alternative Parents
- Diarylethers / Phenoxy compounds / Phenol ethers / O-iodophenols / Iodobenzenes / 1-hydroxy-2-unsubstituted benzenoids / Aryl iodides / Monocarboxylic acids and derivatives / Carboxylic acids / Organoiodides show 3 more
- Substituents
- Diphenylether / Diaryl ether / Phenoxy compound / 2-halophenol / 2-iodophenol / Phenol ether / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Halobenzene / Iodobenzene show 14 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine.
- Gene Name
- THRB
- Uniprot ID
- P10828
- Uniprot Name
- Thyroid hormone receptor beta
- Molecular Weight
- 52787.16 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 09:10